Síndrome de respuesta inflamatoria sistémica por ticagrelor / Systemic inflammatory response syndrome associated with use of ticagrelor
Medicina (B.Aires)
;
81(5): 837-839, oct. 2021.
Article
in Spanish
| LILACS
| ID: biblio-1351057
RESUMEN
Resumen El ticagrelor es un antiagregante plaquetario que actúa a través de la unión reversible a los receptores P2Y12 de la adenosina-difosfato. En el síndrome coronario agudo, ha demostrado reducir el riesgo de eventos cardiovasculares mayores como infarto de miocardio, accidente cerebrovascular y muerte. Si bien se han descripto en detalle ciertas complicaciones hemorrágicas, renales, hepáticas y respiratorias por el uso del ticagrelor, otros efectos adversos menos frecuentes de la droga no han sido adecuadamente escla recidos. Presentamos el caso de un paciente con un síndrome de respuesta inflamatoria sistémica secundario al uso de ticagrelor.
ABSTRACT
Abstract Ticagrelor is anantiplatelet agent which acts through reversible binding to the P2Y12 adenosine-diphosphate recep tors. In acute coronary syndromes it has been shown to reduce the risk of major cardiovascular events such as myocardial infarction, stroke and death. Although some hemorrhagic, kidney, liver and respiratory complications have been described in detail with the use of ticagrelor, other less frequent adverse effects are not so well clari fied. We report the case of a patient with a systemic inflammatory response syndrome secondary to the use of ticagrelor.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Acute Coronary Syndrome
/
Myocardial Infarction
Type of study:
Risk factors
Limits:
Humans
Language:
Spanish
Journal:
Medicina (B.Aires)
Journal subject:
Medicine
Year:
2021
Type:
Article
Affiliation country:
Argentina
Institution/Affiliation country:
Hospital General de Agudos Dr. Juan A. Fernández/AR
Similar
MEDLINE
...
LILACS
LIS